Candel Therapeutics Analyst Ratings
Candel Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/02/2022 | 511.11% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/31/2022 | 566.67% | BMO Capital | $18 → $12 | Maintains | Outperform |
| 11/19/2021 | 900% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 400% | UBS | → $9 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1122.22% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 08/23/2021 | 733.33% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/02/2022 | 511.11% | HC Wainwright公司 | → $11 | 開始承保 | →購買 |
| 03/31/2022 | 566.67% | 蒙特利爾銀行資本 | $18 → $12 | 維護 | 跑贏大盤 |
| 11/19/2021 | 900% | 蒙特利爾銀行資本 | → $18 | 開始承保 | →跑贏大盤 |
| 08/23/2021 | 400% | 瑞銀集團 | → $9 | 開始承保 | →購買 |
| 08/23/2021 | 1122.22% | 傑富瑞 | → $22 | 開始承保 | →購買 |
| 08/23/2021 | 733.33% | 瑞士信貸 | → $15 | 開始承保 | →跑贏大盤 |
What is the target price for Candel Therapeutics (CADL)?
秋茄治療公司(CADL)的目標價格是多少？
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by HC Wainwright & Co. on December 2, 2022. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 511.11% upside). 2 analyst firms have reported ratings in the last year.
凱德爾治療公司(納斯達克代碼：CADL)的最新目標價是由HC Wainwright&Co.於2022年12月2日報道的。這家分析公司將目標價定為11美元，預計CADL12個月內將升至(可能上漲511.11%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Candel Therapeutics (CADL)?
Candel Treeutics(CADL)的最新分析師評級是什麼？
The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by HC Wainwright & Co., and Candel Therapeutics initiated their buy rating.
坎德爾治療公司(納斯達克代碼：CADL)的最新分析師評級由HC Wainwright&Co.提供，坎德爾治療公司啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Candel Treeutics(CADL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on December 2, 2022 so you should expect the next rating to be made available sometime around December 2, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Candel Treeutics的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Candel治療公司的最後一次評級是在2022年12月2日提交的，所以你應該預計下一次評級將在2023年12月2日左右的某個時候提供。
Is the Analyst Rating Candel Therapeutics (CADL) correct?
分析師對Candel Treeutics(CADL)的評級正確嗎？
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a initiated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $1.80, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Candel Treateutics(CADL)評級是以0.00美元至11.00美元的目標價啟動的。秋茄治療公司(CADL)目前的交易價格為1.80美元，在分析師的預測範圍內。